Biochemical and Biophysical Research Communications
Regular ArticleCloning of P2Y6 cDNAs and Identification of a Pseudogene: Comparison of P2Y Receptor Subtype Expression in Bone and Brain Tissues
References (29)
- et al.
Annu. Rev. Pharmacol. Toxicol.
(1995) - et al.
Pharmacol. Ther.
(1994) TiPS
(1997)- et al.
Proc. Natl. Acad. Sci. USA
(1993) Proc. Natl. Acad. Sci. USA
(1994)- et al.
Am. J. Respir. Cell. Mol. Biol.
(1995) J. Biol. Chem.
(1995)- et al.
J. Biol. Chem.
(1995) J. Bone Miner. Res.
(1992)- et al.
J. Bone Miner. Res.
(1991)
Am. J. Physiol.
J. Bone Min. Res.
Molecular Cloning: A Laboratory Manual
Current Protocols in Molecular Biology
Cited by (77)
The expression of the P2Y<inf>6</inf> receptor is regulated at the transcriptional level by p53
2020, Biochemical and Biophysical Research CommunicationsThe role of extracellular ATP-mediated purinergic signaling in bone, cartilage, and tooth tissue
2014, Journal of Oral BiosciencesCitation Excerpt :All of these studies indicate a prominent role of ATP-mediated purinergic signaling in bone. Importantly, osteoblasts have the potential to express all of the P2Y and P2X receptors [20,23–25]. The expression of these receptors, in some cases, appears to be context- and/or species-dependent.
The regulation of osteoblast function and bone mineralisation by extracellular nucleotides: The role of P2X receptors
2012, BoneCitation Excerpt :Studies in the early 1990s demonstrated that extracellular nucleotides act on osteoblast-like cells to transiently increase Ca2 + and induce the formation of inositol triphosphate (IP3) [9]; pharmacological profiles suggested the expression of P2Y1- and P2Y2-like receptors [10–12]. A number of laboratories have since reported the expression of multiple P2 receptor subtypes by osteoblasts [13–18]. Osteoblasts are known to express at least seven different P2 receptor subtypes (P2X2, P2X5, P2X7, P2Y1, P2Y2, P2Y4 and P2Y6) in a differentiation-dependent manner [17].
Molecular Pharmacology, Physiology, and Structure of the P2Y Receptors
2011, Advances in PharmacologyPurinergic signalling and bone remodelling
2010, Current Opinion in Pharmacology
- 1
To whom correspondence and reprint requests should be addressed at Novartis Pharma Inc., Postfach, CH-4002 Basel, Switzerland. Fax: +41 (61) 696-4145. E-mail: graeme.bilbe@pharma. novartis.com.